Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Axi-Cel Reinfusion (Axi-Cel-2) in High-Risk LBCL
NCT05794958Phase 1Recruiting
- Sponsor
- Stanford University
- Start
- May 2023
- Primary completion
- Apr 2038
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of axicabtagene ciloleucel in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Stanford University. Primary endpoint: Incidence of toxicities and dose limiting toxicity (DLT) of a second dose of AxiCel at 28 days. Started May 2023; status: recruiting.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05794958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05794958.